Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: An open study with thirty-five adult patients

Arthritis and Rheumatism

Volumn 46, Issue 2, 2002, Pages 467-474

  Cherin, P ^a   Pelletier, S ^a   Teixeira, A ^a   Laforet, P ^a   Genereau, T ^a   Simon, A ^a   Maisonobe, T ^a   Eymard, B ^a   Herson, S ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; ESOPHAGUS DISEASE; FEMALE; FOLLOW UP; HUMAN; LEUKAPHERESIS; LONG TERM CARE; MALE; MUSCLE STRENGTH; NONPARAMETRIC TEST; PLASMAPHERESIS; POLYMYOSITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANK SUM TEST; REMISSION; SCORING SYSTEM; SIDE EFFECT; STUDENT T TEST; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; CHRONIC DISEASE; CREATINE KINASE; ESOPHAGEAL DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; POLYMYOSITIS; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 0036172213     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10053     Document Type: Article

References (42)

1. Polymyositis, dermatomyositis and inclusion body myositis
2. Mononuclear cells in myopathies: Quantification of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implication for the pathogenesis of the different inflammatory myopathies
3. Mechanisms of lysis by activated cytotoxic cells expressing perforin and granzyme-B genes and the protein TIA-1 in muscle biopsies of myositis
4. Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy
5. Microvascular deposition of complement membrane attack complex in dermatomyositis
6. Recognition and management of myositis
7. Treatment of inclusions body myositis
8. Intravenous immunoglobulin in polymyositis and dermatomyositis
9. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients
10. Intravenously-administered immunoglobulins as first-choice agent in juvenile dermatomyositis
11. Dermatomyositis in a patient under chronic hemodialysis: Treatment with intravenous immunoglobulins
12. Intravenous immune globulin for dermatomyositis
13. Indications of intravenous gammaglobulin therapy in inflammatory myopathies
14. Treatment of childhood dermatomyositis with high dose intravenous immunoglobulin
15. Efficacy of intravenous immunoglobulin therapy in a case of juvenile dermatomyositis
16. Intravenous immunoglobulin therapy in juvenile dermatomyositis
17. High-dose immunoglobulin therapy for a patient with dermatomyositis
18. Cutaneous ulcers of refractory adult dermatomyositis responsive to intravenous immunoglobulin
19. Intravenous immunoglobulin treatment in a girl with juvenile dermatomyositis
20. Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions
21. High dose intravenous immunoglobulin (IVIg) in dermatomyositis: Clinical responses and effect on sIL-2R levels
22. Down-regulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin
23. A controlled trial of high dose intravenous immune globulin, infusions as treatment for dermatomyositis
24. Inhibition of complement activation by intravenous immunoglobulins
25. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments
26. polymyositis and dermatomyositis
27. Autoimmune diseases, IgA deficiency and intravenous immunoglobulin treatment
28. Intravenous gammaglobulin as first line therapy in polymyositis and dermatomyositis: A report of 11 cases
29. Evaluation of muscle disability in adult polymyositis and dermatomyositis with a functional assessment score
30. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases
31. A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups
32. Expression of HLA-DR and its enhancing molecules in muscle fibers in polymyositis
33. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies
34. Cytokines in the muscle tissue of idiopathic inflammatory myopathies: Implications for immunopathogenesis and therapy
35. Expression of selectin families and their ligand sialyl Lewis X in the muscles of inflammatory myopathies: An immunohistochemical study
36. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies
37. Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies
38. Increased expression of interleukin lalpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis
39. The inhibition of apoptosis in myositis and in normal muscle cells
40. Frequency of relapses in patients with polymyositis and dermatomyositis
41. Relapse of polymyositis after prolonged remission